National Institute for Health and Clinical Excellence

Health written question – answered on 12th November 2010.

Alert me about debates like this

Photo of John Leech John Leech Liberal Democrat, Manchester, Withington

To ask the Secretary of State for Health how many medicines have been assessed by the National Institute for Health and Clinical Excellence under end-of-life criteria since it was established.

Photo of Simon Burns Simon Burns The Minister of State, Department of Health

Information on published appraisals to which a National Institute for Health and Clinical Excellence Appraisal Committee applied the flexibility for the appraisal of potentially life extending treatments for patients at the end of their lives is shown in the table.

Publication date Appraisal title Recommendation1
March 2009 Sunitinib for the first line treatment of advanced and/or metastatic renal cell carcinoma Recommended
June 2009 Lenalidomide for the treatment of multiple myeloma Recommended
August 2009 Sorafenib for the first and second-line treatment of advanced and/or metastatic renal cell carcinoma Not recommended
Temsirolimus for the first-line treatment of advanced and/or metastatic renal cell carcinoma Not recommended
September 2009 Sunitinib for the treatment of gastrointestinal stromal tumours Recommended
November 2009 Topotecan for the treatment of lung cancer (small-cell) Recommended
February 2010 Trabectedin for soft tissue sarcoma Recommended
May 2010 Sorafenib for the treatment of hepatocellular carcinoma Not recommended
June 2010 Pemetrexed for the maintenance treatment of non-small-cell lung cancer Recommended
Note:

Where a treatment is "recommended", it is recommended in line with the marketing authorisation or in line with clinical practice.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.